Response to COVID19

The rapid increase in patients with COVID-19 and the urgent need to identify safe and effective therapies has already engaged both the Hub OCR and the CHPS unit. OCR is charged with ensuring the rapid and compliant design and reduction to practice of clinical trials and the CHPS unit is the site for phenotypic evaluation in some of these trials such as interventional and observational studies of health care workers. Given the diverse basic, translational and clinical research studies that are being conducted we have established a Research Oversight Committee, chaired by Dr. FitzGerald and including Dr. Meagher who leads OCR, Dr. Rader who heads the Penn Medicine Biobank, and Lorri Schieri, ex officio, who is the senior administrator for the ITMAT, OCR, and PMBB.